Stocksigma LogoStocksigma Logo

Neuland Laboratories Reports Q2 FY27 Financial Results

Neuland Laboratories reported a standalone Q2 FY27 revenue decline of 11.4% YoY to ₹457.2 Cr (-29.7% QoQ)

Neuland Laboratories Reports Q2 FY27 Financial Results

Neuland Laboratories Ltd · Press Release · 03 Nov 2026, 9:45 pm

Neuland Laboratories Reports Q2 FY27 Financial Results Neuland Laboratories reported a standalone Q2 FY27 revenue decline of 11.4% YoY to ₹457.2 Cr (-29.7% QoQ). EBITDA dropped 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. For H1 FY27, revenue rose 35.6% YoY to ₹1,107.2 Cr and PAT surged 80.2% YoY to ₹198.5 Cr. Working capital cycle improved to 104 days from 155 days. Capex reached ₹261 Cr, supporting R&D and peptide capacity expansions.

Original exchange filing (PDF)

More announcements from Neuland Laboratories Ltd

All Neuland Laboratories Ltd announcements